2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,849,402 shares of the company’s stock, valued at approximately $5,414,000. Whitehawk Therapeutics comprises 0.1% of Avoro Capital Advisors LLC’s portfolio, making the stock its 29th largest holding. Avoro Capital Advisors LLC owned 6.05% of Whitehawk Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP bought a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at approximately $84,000. Peapod Lane Capital LLC bought a new stake in Whitehawk Therapeutics during the 3rd quarter worth approximately $577,000. Finally, Vanguard Group Inc. bought a new stake in Whitehawk Therapeutics during the third quarter valued at approximately $2,552,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

Whitehawk Therapeutics Stock Performance

Shares of NASDAQ:WHWK opened at $3.91 on Friday. The firm has a market cap of $184.28 million, a price-to-earnings ratio of 8.32 and a beta of 0.51. The firm has a fifty day moving average price of $3.02 and a 200 day moving average price of $2.48. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Monday, December 29th. JonesTrading initiated coverage on shares of Whitehawk Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. Finally, Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.50.

Whitehawk Therapeutics Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.